August 2007

The Cutting Edge

Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Dermatol. 2007;143(8):1062. doi:10.1001/archderm.143.8.1062

In this issue of the Archives, Weinfeld1 presents a novel use of botulinum toxin type A for a very difficult to treat condition, notalgia paresthetica. The 2 patients described in her article were resistant to all standard therapeutic modalities (none of which are usually effective), whereas 1 to 2 treatments with botulinum toxin type A eliminated or greatly reduced their symptoms for at least 1 year. This case report exemplifies the ideal Cutting Edge article. It presents the case of a patient with a condition that is either difficult to effectively treat with existing methods or a patient who is resistant to treatment and describes a novel treatment not previously reported. Ideally, it should be a treatment that is easily available to the physician, such as the botulinum toxin type A used in Weinfeld's report.1

First Page Preview View Large
First page PDF preview
First page PDF preview